77. Gould CV, Umscheid CA, Agarwal RK, Kuntz G, Pegues DA, Healthcare Infection Control Practices Advisory C. Guideline for prevention of catheter-associated urinary tract infections 2009. Infect Control Hosp Epidemiol. 2010;31(4):319-326. 78. Mody L, Greene MT, Meddings J, et al. A National Implementation Project to Prevent Catheter-Associated Urinary Tract Infection in Nursing Home Residents. JAMA Intern Med. 2017;177(8):1154-1162. 79. Doyle JS, Buising KL, Thursky KA, Worth LJ, Richards MJ. Epidemiology of infections acquired in intensive care units. Semin Respir Crit Care Med. 2011;32(2):115-138. 80. Dixon JJ, Steele M, Makanjuola AD. Anti- microbial locks increase the prevalence of Staphylococcus aureus and antibiotic-resistant Enterobacter: observational retrospective cohort study. Nephrol Dial Transplant. 2012;27(9):3575-3581. 81. Klompas M, Branson R, Eichenwald EC, et al. Strategies to prevent ventilator-associated pneumonia in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol. 2014;35(8):915-936. 82. Camus C, Salomon S, Bouchigny C, et al. Short- term decline in all-cause acquired infections with the routine use of a decontamination regimen combining topical polymyxin, tobramycin, and amphotericin B with mupirocin and chlorhexidine in the ICU: a single-center experience. Crit Care Med. 2014;42(5):1121- 1130. 83. Institute of Medicine. Preventing medication errors: Quality Chasm Series. Washington DC: National Academies Press; 2006. 84. Wolf ZR. Strategies to Reduce Patient Harm From Infusion-Associated Medication Errors: A Scoping Review. J Infus Nurs. 2018;36(1):58- 65. 85. Giuliano KK. IV Smart Pumps: The Impact of a Simplified User Interface on Clinical Use. Biomed Instrum Technol. 2015;Suppl:13-21. 86. Tomczyk S, Zanichelli V, Grayson ML, et al. Control of Carbapenem-resistant Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa in Healthcare Facilities: A Systematic Review and Reanalysis of Quasi-experimental Studies. Clin Infect Dis. 2019;68(5):873-884. 87. European Center for Disease Prevention and Control. Systematic Review of the Effectiveness of Infection Control Measures To Prevent the Transmission of Carbapenemase-Producing Enterobacteriaceae Through Cross-Border Transfer of Patients. https://www.ecdc.europa. eu/en/publications-data/systematic-review- effectiveness-infection-control-measures- prevent-transmission. Accessed October 20, 2021.
88. Goodman KE, Simner PJ, Klein EY, et al. How frequently are hospitalized patients colonized with carbapenem-resistant Enterobacteriaceae (CRE) already on contact precautions for other indications? Infect Control Hosp Epidemiol. 2018;39(12):1491-1493. 89. Borer A, Eskira S, Nativ R, et al. A multifaceted intervention strategy for eradication of a hospital-wide outbreak caused by carbapenem-resistant Klebsiella pneumoniae in Southern Israel. Infect Control Hosp Epidemiol. 2011;32(12):1158-1165. 90. The Joint Commission. Hot Topics: Transitions of Care: the need for a more effective approach to continuing patient care. https:// pdf4pro.com/view/hot-topics-transitions-of- care-joint-commission-c1f98.html. Accessed October 20, 2021. 91. Watts E, Rayman G, Diabetes UK. Making Hospitals Safe for Diabetes Patients. https:// www.diabetes.org.uk/resources-s3/2018-10/ Making%20Hospitals%20safe%20for%20 people%20with%20diabetes_FINAL.pdf. Accessed October 20, 2021. 92. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345(19):1359-1367. 93. National Center for Health Statistics. Health, United States, 2016: With Chartbook on long- term trends in health. 2017. 94. Classen DC, Jaser L, Budnitz DS. Adverse drug events among hospitalized Medicare patients: epidemiology and national estimates from a new approach to surveillance. Jt Comm J Qual Patient Saf. 2010;36(1):12-21. 95. Ocampo CC, Garcia-Cardenas V, Martinez- Martinez F, Benrimoj SI, Amariles P, Gastelurrutia MA. Implementation of medication review with follow-up in a Spanish community pharmacy and its achieved outcomes. Int J Clin Pharm. 2015;37(5):931-940. 96. Ailabouni N, Mangin D, Nishtala PS. DEFEAT- polypharmacy: deprescribing anticholinergic and sedative medicines feasibility trial in residential aged care facilities. Int J Clin Pharm. 2019;41(1):167-178. 97. Petersen AW, Shah AS, Simmons SF, et al. Shed-MEDS: pilot of a patient-centered deprescribing framework reduces medications in hospitalized older adults being transferred to inpatient postacute care. Ther Adv Drug Saf. 2018;9(9):523-533. 98. McKean M, Pillans P, Scott IA. A medication review and deprescribing method for hospitalised older patients receiving multiple medications. Intern Med J. 2016;46(1):35-42. 99. Tannenbaum C, Martin P, Tamblyn R, Benedetti A, Ahmed S. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med. 2014;174(6):890-898.
100. Martin P, Tamblyn R, Benedetti A, Ahmed S, Tannenbaum C. Effect of a Pharmacist-Led Educational Intervention on Inappropriate Medication Prescriptions in Older Adults: The D-PRESCRIBE Randomized Clinical Trial. JAMA. 2018;320(18):1889-1898. 101. Lenander C, Elfsson B, Danielsson B, Midlov P, Hasselstrom J. Effects of a pharmacist- led structured medication review in primary care on drug-related problems and hospital admission rates: a randomized controlled trial. Scand J Prim Health Care. 2014;32(4):180- 186. 102. Chan DC, Chen JH, Wen CJ, Chiu LS, Wu SC. Effectiveness of the medication safety review clinics for older adults prescribed multiple medications. J Formos Med Assoc. 2014;113(2):106-113. 103. Campins L, Serra-Prat M, Gozalo I, et al. Randomized controlled trial of an intervention to improve drug appropriateness in community-dwelling polymedicated elderly people. Fam Pract. 2017;34(1):36-42. 104. Gibert P, Cabaret M, Moulis M, et al. Optimizing medication use in elderly people in primary care: Impact of STOPP criteria on inappropriate prescriptions. Arch Gerontol Geriatr. 2018;75:16-19. 105. Hannou S, Voirol P, Pannatier A, et al. Pharmacist intervention acceptance for the reduction of potentially inappropriate drug prescribing in acute psychiatry. Int J Clin Pharm. 2017;39(6):1228-1236. 106. Centers for Disease Control & Prevention. Understanding the epidemic. https://www. cdc.gov/drugoverdose/epidemic/index.html. Published 2019. Accessed April 1 2019. 107. Centers for Disease Control & Prevention. Vital signs: overdoses of prescription opioid pain relievers---United States, 1999--2008. MMWR Morbidity and mortality weekly report. 2011;60(43):1487-1492. 108. Centers for Disease Control & Prevention. Increse in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. https://emergency.cdc.gov/han/2020/ han00438.asp?ACSTrackingID=USCDC_511- DM44961&ACSTrackingLabel=HAN%20 438%20-%20General%20 Public&deliveryName=USCDC_511- DM44961. Accessed December 28, 2020. 109. Centers for Disease Control & Prevention. 12 Month-ending provisional number of drug overdose deaths. https://www.cdc.gov/nchs/ nvss/vsrr/drug-overdose-data.htm. Accessed December 28, 2020. 110. Centers for Disease Control & Prevention. Opioid overdose: Understanding the Epidemic. https://www.cdc.gov/drugoverdose/images/3- waves-2019.PNG. Published 2021. Accessed June 10, 2021.
115
Powered by FlippingBook